--- title: "LB Pharmaceuticals (LBRX) news: IPO and offering" url: "https://aibio.space/companies/lb-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LBRX IPO and offering news: LB Pharmaceuticals prices IPO of 19,000,000 shares at $15.00. LB Pharmaceuticals Inc (NASDAQ: LBRX), United States." --- LBRX LB Pharmaceuticals Inc NASDAQ · United States # LB Pharmaceuticals (LBRX) news LBRX IPO and offering news Financings · 2026-07-29 ## [LB Pharmaceuticals agrees to $150 million private placement at $34.94 a share](https://aibio.space/news/lb-pharmaceuticals-agrees-150-million-private-placement-34-94-share/) The company is selling 3,577,560 shares and pre-funded warrants for up to 715,513 shares to institutional investors. The deal is expected to close on or about July 30, 2026, and the 2025 10-K filed in March 2026 shows net loss of $25.2 million for the year. ## Latest LB Pharmaceuticals news 1. 2026-02-05 Financings [LB Pharmaceuticals agrees to $100.0 million private placement at $21.17 a share](https://aibio.space/news/lb-pharmaceuticals-agrees-100-0-million-private-placement-21-17-share/) LB Pharmaceuticals agreed to sell 3,306,571 shares and pre-funded warrants for up to 1,417,107 shares to institutional investors. It plans to use the proceeds for a Phase 2 trial of LB-102 in major depressive disorder and for general corporate purposes. 2. 2025-09-12 Financings [LB Pharmaceuticals prices IPO of 19,000,000 shares at $15.00](https://aibio.space/news/lb-pharmaceuticals-prices-ipo-19-000-000-shares-15-00/) The offering totals $285,000,000, and the shares are approved for listing on Nasdaq under LBRX. Proceeds to the company are $265,050,000 before expenses, and the company's lead drug has a Phase 3 trial still ahead. ## LB Pharmaceuticals at a glance - **Ticker**: LBRX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $327.8 million ### Related companies - [Biomea Fusion](https://aibio.space/companies/biomea-fusion/) NASDAQ: BMEA - [Adicet Bio](https://aibio.space/companies/adicet-bio/) NASDAQ: ACET - [Semnur Pharmaceuticals](https://aibio.space/companies/semnur-pharmaceuticals/) OTC: SMNR - [BlossomHill Therapeutics](https://aibio.space/companies/blossomhill-therapeutics/) NASDAQ: BLSM - [Insmed](https://aibio.space/companies/insmed/) NASDAQ: INSM - [Silo Pharma](https://aibio.space/companies/silo-pharma/) NASDAQ: SILO - [Aligos Therapeutics](https://aibio.space/companies/aligos-therapeutics/) NASDAQ: ALGS - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) NASDAQ: ACAD ### Also on NASDAQ - [Eledon Pharmaceuticals](https://aibio.space/companies/eledon-pharmaceuticals/) ELDN - [QTREX Quantum](https://aibio.space/companies/qtrex-quantum/) QTEX - [Creative Medical Technology Holdings](https://aibio.space/companies/creative-medical-technology/) CELZ - [Vanda Pharmaceuticals](https://aibio.space/companies/vanda-pharmaceuticals/) VNDA - [Scilex Holding](https://aibio.space/companies/scilex/) SCLX - [Tyra Biosciences](https://aibio.space/companies/tyra-biosciences/) TYRA ## LB Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$16.7 million](https://www.sec.gov/Archives/edgar/data/1691082/000119312526126368/) | [$51.2 million](https://www.sec.gov/Archives/edgar/data/1691082/000119312526126368/) | | Net income (loss) | [-$25.2 million](https://www.sec.gov/Archives/edgar/data/1691082/000119312526126368/) | [-$63.1 million](https://www.sec.gov/Archives/edgar/data/1691082/000119312526126368/) | | Cash from operations | [-$35.2 million](https://www.sec.gov/Archives/edgar/data/1691082/000119312526126368/) | [-$53.1 million](https://www.sec.gov/Archives/edgar/data/1691082/000119312526126368/) | | Cash and equivalents | [$250.2 million](https://www.sec.gov/Archives/edgar/data/1691082/000119312526343490/) | [$23.0 million](https://www.sec.gov/Archives/edgar/data/1691082/000119312526126368/) | | Short-term investments | [$45.0 million](https://www.sec.gov/Archives/edgar/data/1691082/000119312526343490/) | [$5.0 million](https://www.sec.gov/Archives/edgar/data/1691082/000119312526126368/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $283.1 million, plus short-term investments of $44.7 million, $327.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about LB Pharmaceuticals When did LB Pharmaceuticals go public? Our latest story on this, dated Sep 12, 2025: "LB Pharmaceuticals prices IPO of 19,000,000 shares at $15.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lb-pharmaceuticals-prices-ipo-19-000-000-shares-15-00/). Has LB Pharmaceuticals raised money recently? Our latest story on this, dated Jul 29, 2026: "LB Pharmaceuticals agrees to $150 million private placement at $34.94 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lb-pharmaceuticals-agrees-150-million-private-placement-34-94-share/). What is the ticker symbol of LB Pharmaceuticals? LB Pharmaceuticals Inc trades under the ticker LBRX on NASDAQ. Where is LB Pharmaceuticals listed? LB Pharmaceuticals Inc is listed on NASDAQ. What is the SEC CIK of LB Pharmaceuticals? The SEC Central Index Key (CIK) for LB Pharmaceuticals Inc is 1691082. Its filings are on SEC EDGAR. How many shares does LB Pharmaceuticals have outstanding? 32,259,175 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is LB Pharmaceuticals listed under? Our directory records LB Pharmaceuticals Inc under United States. What does LB Pharmaceuticals do? Our directory classifies LB Pharmaceuticals Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of LB Pharmaceuticals? The ISIN recorded for LB Pharmaceuticals Inc is US50180M1080. Does aibio.space cover LB Pharmaceuticals? aibio.space lists LB Pharmaceuticals Inc among 2,820 public biotech companies and publishes its news here as stories appear. Where is LB Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. Is LB Pharmaceuticals profitable? LB Pharmaceuticals Inc reported a net loss of $25.2 million for the fiscal year ended Dec 31, 2025, and used $35.2 million of cash in operations, per its annual report to the SEC. How much does LB Pharmaceuticals spend on research and development? $16.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does LB Pharmaceuticals have? $327.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest LB Pharmaceuticals (LBRX) stock news? Our latest story on LB Pharmaceuticals, dated Jul 29, 2026: "LB Pharmaceuticals agrees to $150 million private placement at $34.94 a share". The company is selling 3,577,560 shares and pre-funded warrants for up to 715,513 shares to institutional investors. The deal is expected to close on or about July 30, 2026, and the 2025 10-K filed in March 2026 shows net loss of $25.2 million for the year. [Source](https://aibio.space/news/lb-pharmaceuticals-agrees-150-million-private-placement-34-94-share/). ## Investor discussion: LB Pharmaceuticals Members talk about LB Pharmaceuticals (LBRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at LB Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-09-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1691082/000119312526391358/d157620dex991.htm) 2. 2026-09-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1691082/000119312526381076/d26110dex991.htm) 3. 2026-07-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1691082/000119312526322208/d156920dex991.htm) 4. 2026-02-05 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1691082/000119312526038539/d943290dex991.htm) 5. 2025-11-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1691082/000119312525276070/d79831dex991.htm) 6. 2025-11-06 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1691082/000119312525268174/lbrx-20250930.htm) 7. 2025-09-12 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1691082/000119312525201757/d12080d424b4.htm) 8. 2025-08-22 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080ds1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LBRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-LBRX/). ## SEC filings and registration - **SEC name**: Lb Pharmaceuticals Inc - **CIK**: 1691082 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: LBRX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 575 MADISON AVENUE, NEW YORK, NY, 10022 - **Phone**: 917-450-6581 - **Shares outstanding**: 32,259,175 as of 2026-08-05 (10-Q filed 2026-08-11) - **Former names**: LB PHARMACEUTICALS INC. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1691082/000119312526391358/d157620d8k.htm) filed 2026-09-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1691082/000119312526381076/d26110d8k.htm) filed 2026-09-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1691082/000119312526343490/lbrx-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1691082/000119312526343479/d303033d8k.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1691082/000119312526322208/d156920d8k.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1691082/000119312526311357/d173035d8k.htm) filed 2026-07-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1691082/000119312526265867/d221514d8k.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1691082/000119312526263724/d138757d8k.htm) filed 2026-06-09 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001691082), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details LB Pharmaceuticals Inc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LBRX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: LB Pharmaceuticals Inc - **Ticker**: LBRX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US50180M1080 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LBRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/lb-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "LB Pharmaceuticals (LBRX) news: IPO and offering", 2026-10-31, https://aibio.space/companies/lb-pharmaceuticals/